VRTX · NASDAQ-GS
Consensus is $4.40 EPS for Sep 2026 across 6 estimates, ranging $4.33 to $4.48.
No consensus figures are available, so the quarter cannot be judged against an external expectation; reported revenue rose 12% year over year to $3,333.9 million and net income increased to $1,099.8 million from $1,032.9 million. CF remained the foundation, with revenue up 11% to $3,207.9 million as ALYFTREK grew 266% to $573.6 million, more than offsetting a 2% decline in TRIKAFTA/KAFTRIO and a 29% drop in other CF products. Diversification contributed strongly: CASGEVY rose 151% to $76.4 million and JOURNAVX rose 313% to $49.6 million. Growth accelerated versus Q2 2025's 3.0 billion revenue level, with U.S. sales up 11% and ex-U.S. sales up 14%. Profit growth was constrained by cost of sales rising to 14.7% of product revenue from 13.8% and higher commercialization spending, as total R&D, acquired in-process R&D and SG&A reached $1.6 billion from $1.4 billion.
No formal numerical revenue, earnings, margin or capex guidance range was provided in the supplied material, and there is no prior guide to compare against. Management did provide operating expectations: it expects continued investment in research programs, new product launches and the pipeline; expects full enrollment in the AMPLITUDE Phase 2/3 trial in the second half of 2026; and expects interim data in early 2027. The FDA's PDUFA target date for povetacicept in IgA nephropathy is November 30, 2026. Management expects the approximately $10.0 billion Crinetics acquisition to close in Q3 2026, subject to customary conditions.
